 |
Caffeine - Diagnostic use
Research News and Information
Definition of 'Caffeine'A methylxanthine naturally occurring in some beverages and also used as a pharmacological agent. Caffeine's most notable pharmacological effect is as a central nervous system stimulant, increasing alertness and producing agitation. It also relaxes SMOOTH MUSCLE, stimulates CARDIAC MUSCLE, stimulates DIURESIS, and appears to be useful in the treatment of some types of headache. Several cellular actions of caffeine have been observed, but it is not entirely clear how each contributes to its pharmacological profile. Among the most important are inhibition of cyclic nucleotide PHOSPHODIESTERASES, antagonism of ADENOSINE RECEPTORS, and modulation of intracellular calcium handling. |
Monday, March 22, 2010
Panic disorder and social anxiety disorder subtypes in a caffeine challenge test.
18 Aug 2009 
Studies have demonstrated the vulnerability of anxiety disorder patients to challenge tests. Our aim was to observe if panic disorder (PD) patients and generalized social anxiety disorder (GSAD) and performance social anxiety disorder (PSAD) ... Read more...
20 Oct 2008 A 33-year-old woman developed severe post-lumbar puncture headaches in the course of work-up for multiple sclerosis. Immediately after receiving treatment with intravenous caffeine, she became blind and experienced a generalized tonic-clonic ... Read more...
[In-vivo diagnosis of malignant hyperthermia susceptibility: a microdialysis study]
30 Jul 2008 BACKGROUND: In malignant hyperthermia (MH), volatile anesthetics induce hypermetabolism, lactic acidosis and rhabdomyolysis in predisposed patients. The authors hypothesized that intramuscular caffeine and halothane application would increase local ... Read more...
Latest indexed articles for 'Caffeine - Diagnostic use'
These are the very latest articles for this heading:
- Panic disorder and social anxiety disorder subtypes in a caffeine challenge test. 18 Aug 2009
- You're "hot" from pumping iron?
27 Feb 2009 - Posterior reversible encephalopathy syndrome after intravenous caffeine for post-lumbar puncture headaches. 20 Oct 2008
- [In-vivo diagnosis of malignant hyperthermia susceptibility: a microdialysis study] 30 Jul 2008
- [Anesthesia in malignant hyperthermia] 28 Feb 2008
- [Methods of taste sensitivity examination] 30 Dec 2007
- A caffeine challenge test in panic disorder patients, their healthy first-degree relatives, and healthy controls. 30 Dec 2007
- Fulminant malignant hyperthermia. 30 Dec 2007
- Is electrogustometry useful for screening abnormalities of taste? 10 Oct 2007
- Growth hormone does not alter CYP2A6 activity in growth hormone-deficient children. 7 Oct 2007
- Auditory hallucinations during a caffeine challenge in a patient with panic disorder. 26 Jun 2007
- Caffeine and 35% carbon dioxide challenge tests in panic disorder. 30 May 2007
- Male preponderance of patients testing positive for malignant hyperthermia susceptibility. 29 Apr 2007
- Development of the "Inje cocktail" for high-throughput evaluation of five human cytochrome P450 isoforms in vivo. 26 Mar 2007
- Caffeine challenge test in panic disorder and depression with panic attacks. 28 Jan 2007
- Lack of effect of growth hormone replacement therapy on CYP1A2 and xanthine oxidase activities in growth hormone-deficient children. 10 Jan 2006
- Validity and new malignant hyperthermia diagnostic procedures. 30 Dec 2005
- Oral contraceptives containing ethinyl estradiol and gestodene markedly increase plasma concentrations and effects of tizanidine by inhibiting cytochrome P450 1A2. 29 Sep 2005
- Malignant hyperthermia: update on susceptibility testing. 13 Jun 2005
- A simple test for acetylator phenotype using caffeine. 1984.
29 Nov 2004
See a longer list of these articles.
Technical information about 'Caffeine'
Definition: A methylxanthine naturally occurring in some beverages and also used as a pharmacological agent. Caffeine's most notable pharmacological effect is as a central nervous system stimulant, increasing alertness and producing agitation. It also relaxes SMOOTH MUSCLE, stimulates CARDIAC MUSCLE, stimulates DIURESIS, and appears to be useful in the treatment of some types of headache. Several cellular actions of caffeine have been observed, but it is not entirely clear how each contributes to its pharmacological profile. Among the most important are inhibition of cyclic nucleotide PHOSPHODIESTERASES, antagonism of ADENOSINE RECEPTORS, and modulation of intracellular calcium handling.
Chemical name: 1H-Purine-2,6-dione, 3,7-dihydro-1,3,7-trimethyl-
Registry Number: 58-08-2
Descriptor UI: D002110
Alternative terms: Caffeine; 1,3,7-Trimethylxanthine; Coffeinum N; Merck dura Brand of Caffeine; Coffeinum Purrum; Berlin-Chemie Brand of Caffeine; Dexitac; Republic Drug Brand of Caffeine; Vivarin; GlaxoSmithKline Brand of Caffeine; No Doz; Bristol-Myers Squibb Brand of Caffeine; Percoffedrinol N; Passauer Brand of Caffeine; Percutaféine; Pierre Fabre Brand of Caffeine; Quick-Pep; Thompson Brand 2 of Caffeine; Caffedrine; Thompson Brand 1 of Caffeine; Durvitan; Seid Brand of Caffeine;
Allowable Qualifiers: administration & dosage; adverse effects; analogs & derivatives; analysis; antagonists & inhibitors; biosynthesis; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; genetics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; secretion; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;
Pharmacological Action: Phosphodiesterase Inhibitors; Central Nervous System Stimulants;
Tree Number: D03.132.960.175; D03.438.759.758.824.175;